查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830318

次世代定序市场（按技术、产品类型、工作流程、最终用户和应用）—全球预测 2025-2032

Next Generation Sequencing Market by Technology, Product Type, Workflow, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，次世代定序市场将成长至 1,257.8 亿美元，复合年增长率为 24.79%。

主要市场统计数据
基准年2024年 213.8亿美元
预计2025年 266.9亿美元
预测年份：2032年 1257.8亿美元
复合年增长率（%） 24.79%

次世代定序的策略方向将技术进步和临床应用与营运重点和相关人员的决策连结起来

次世代定序(NGS) 已从一项利基实验室技术转变为一个塑造生物医学研究、诊断和生物製药创新的基础平台。本介绍概述了技术成熟度、不断扩展的临床应用以及决策者为有效利用 NGS 所必须应对的营运挑战。定序化学、仪器通量和生物资讯学工具集的进步降低了技术门槛，同时在肿瘤学、感染疾病监测和罕见疾病遗传学领域的实际部署也已证明其临床效用。同时，随着定序数据越来越多地为患者护理和治疗发展提供信息，企业对数据品质、互通性和法规遵从性的期望也日益提高。

要了解当前的情况，需要考察不断发展的技术与使用者需求之间的相互作用。研究实验室需要可重复的工作流程，以平衡吞吐量和准确性；临床医生需要可整合到电子健康记录系统中的可操作报告；治疗药物开发人员则依赖高保真基因组数据进行生物标记发现和患者分层。因此，数据储存、可扩展计算和强大的分析流程等基础设施考量正变得与仪器选择同等重要。随着应用的推进，策略性相关人员不仅必须评估短期绩效指标，还必须评估长期营运成本、供应商蓝图和生态系统伙伴关係。

本摘要强调 NGS 现在是一项系统级投资，为以下章节奠定了基础：有效实施取决于将技术能力与工作流程要求和以患者为中心的结果相结合，同时适应不断变化的监管期望和全球供应链动态。

技术、分析和监管趋势的融合正在重新定义定序能力、验证期望和协作部署模型

次世代定序领域正经历一场变革性的转变，这股变革由多元力量共同推动，再形成定序能力与应用。首先，仪器创新持续优先考虑速度、准确性和成本效益，从而实现了诸如快速感染疾病病原体鑑定和即时肿瘤检验等新用例。其次，生物资讯学正从客製化脚本转向日益标准化和验证的流程，其中包含比对、註释和可重复的变异调用，可用于临床报告。这些方法上的进步正在减少实验室间的差异，并加快获得结果的时间，从而扩大NGS的临床和商业性价值提案。

同时，资料管理和储存模式也在不断发展。相关人员越来越多地采用将云端储存与本地运算相结合的混合架构，以平衡资料主权、延迟和安全性问题。与电子健康记录和临床决策支援工具的整合变得更加无缝，使基因组学见解能够为照护现场决策提供资讯。法律规范正在适应这一现实，更加重视分析和临床检验、将软体视为医疗设备以及参考资料集的来源。最后，学术中心、诊断实验室和生物製药公司之间的伙伴关係正在加速检测和伴随诊断的共同开发，从而改变共同开发模式。这些转变共同创造了一个动态环境，其中技术创新、验证严谨性和生态系统伙伴关係共同决定了 NGS 的采用速度和范围。

2025 年关税如何改变定序供应链、采购行为以及实验室和服务供应商的业务恢復策略

2025年美国加征关税，对次世代定序供应链、筹资策略和成本管理实务产生了多方面的影响，但并未改变基因组技术的基本科学价值。关税影响了设备、试剂和辅助零件的流通，增加了进口到岸成本，并促使各组织重新评估供应商多元化。因此，采购团队加快了区域供应商的资格认证流程，并寻求长期合约以稳定价格和供应承诺。同时，製造商和经销商调整了库存策略，维持更高的缓衝库存，并调整了生产布局，以降低关税相关的中断风险​​。

在营运方面，实验室和服务供应商透过优化试剂利用率、整合订单和协商配套服务协议来吸收关税导致的成本增加。优先考虑临床连续性的机构将重点转移到有效的在地采购和加强服务等级协议，以确保设备执行时间。此外，关税环境促使重新评估资本配置时间表。机构权衡了购买新的高通量测序仪的好处与增加的进口成本和潜在的延误。同时，法规遵循和品管要求仍然是不可协商的，促使对工作流程效率进行投资，以便在采购动态发生动态时仍能维持分析绩效。简而言之，2025 年关税的累积效应加速了供应链弹性规划，并强调了综合筹资策略和营运策略对于维持定序计画的重要性。

综合細項分析，协调技术类型、产品类型、工作流程阶段、最终用户配置文件和应用主导的优先级，以指导策略投资

关键细分洞察揭示了技术优势和工作流程需求的交汇点，从而决定了实施和能力的优先顺序。按技术划分，定序技术包括扩增子定序、基因面板定序、RNA定序、标靶定序、全EXOME子定序 (WES) 和全基因组定序 (WGS)，每种技术在深度、广度和临床效用都达到了不同的平衡，为平台和检测方法的选择提供参考。根据产品类型，产品分为消耗性试剂、仪器和软体服务。消耗性试剂主要包括酵素和套件，仪器包括辅助设备和定序仪，软体服务则分为资料分析软体和服务，这反映了检验分析和可控解读日益增长的重要性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 整合单细胞多体学和空间转录组学以实现精准肿瘤学
  • 拓展长读长定定序在结构变异分析与诊断的应用
  • 采用即时奈米孔定序进行现场感染疾病监测与控制
  • 引进自动化NGS文库製备系统，减少週转时间与错误
  • 人工智慧和机器学习平台的发展加速了NGS数据的分析和解释
  • 直接RNA定序方法的出现提高了转录组分析的准确性和通量
  • 液态生物检体NGS检测在早期癌症检测和微量残存疾病监测的应用日益广泛
  • 整合云端原生生物资讯学流程，实现可扩展且安全的 NGS 资料管理工作流程
  • 扩大基于NGS的肿瘤伴随诊断的监管核准和报销途径
  • 开发合成长读技术来阐明复杂的基因组区域和单倍型定相

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章次世代定序市场（依技术）

  • 定序子定序
  • 基因组定序
  • RNA定序
  • 标靶定序
  • 全EXOME定序（WES）
  • 全基因测序（WGS）

第九章次世代定序市场（依产品类型）

  • 耗材试剂
    • 酵素
    • 套件
  • 装置
    • 辅助设备
    • 序列器
  • 软体服务
    • 数据分析软体
    • 服务

第 10 章次世代定序市场（依工作流程）

  • 数据分析
    • 结盟
    • 评论
    • 变异调用
  • 资料储存
    • 云端储存
    • 本地储存
  • 样品製备
    • 文库製备
    • 准备模板
  • 定序

第 11 章次世代定序市场（依最终用户）

  • 学术研究机构
  • 医疗保健诊断实验室
  • 製药和生物技术公司

第十二章次世代定序市场（按应用）

  • 农业基因组学
  • 携带者筛检
  • 表观基因
  • 法医学基因组学
  • 遗传和罕见疾病
  • 感染疾病
  • 神经基因组学
  • 肿瘤学
  • 药物基因组学

第十三章次世代定序市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章次世代定序市场：按类别

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国次世代定序市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Roche Holding AG
    • QIAGEN NV
    • bioMerieux SA
    • Merck KGaA
    • Oxford Nanopore Technologies Ltd.
    • Agilent Technologies, Inc.
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd.
Product Code: MRR-4312A385A68A

The Next Generation Sequencing Market is projected to grow by USD 125.78 billion at a CAGR of 24.79% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 21.38 billion
Estimated Year [2025] USD 26.69 billion
Forecast Year [2032] USD 125.78 billion
CAGR (%) 24.79%

A strategic orientation to next generation sequencing that ties technological advances and clinical adoption to operational priorities and stakeholder decision-making

Next generation sequencing (NGS) has transitioned from a niche laboratory technique to a foundational platform shaping biomedical research, diagnostics, and biopharmaceutical innovation. This introduction outlines the technological maturation, broadening clinical applications, and operational challenges that decision-makers must reconcile to harness NGS effectively. Advances in sequencing chemistry, instrument throughput, and bioinformatic toolsets have lowered technical barriers, while real-world deployments in oncology, infectious disease surveillance, and rare disease genetics demonstrate tangible clinical utility. At the same time, organizations face rising expectations for data quality, interoperability, and regulatory compliance as sequencing data increasingly informs patient care and therapeutic development.

Understanding the current landscape requires attention to the interplay between technology evolution and user needs. Laboratories seek reproducible workflows that balance throughput with accuracy, clinicians demand actionable reports that integrate into electronic health record systems, and developers of therapeutics rely on high-fidelity genomic data for biomarker discovery and patient stratification. Consequently, infrastructure considerations such as data storage, scalable compute, and robust analysis pipelines have become as important as instrument selection. As adoption deepens, strategic stakeholders must evaluate not only immediate performance metrics but also long-term operational costs, vendor roadmaps, and ecosystem partnerships.

This summary sets the scene for subsequent sections by emphasizing that NGS is now a systems-level investment. Effective deployment hinges on aligning technical capabilities with workflow requirements and patient-centric outcomes, while adapting to evolving regulatory expectations and global supply chain dynamics.

Converging technological, analytical, and regulatory trends that are redefining sequencing capabilities, validation expectations, and collaborative deployment models

The landscape of next generation sequencing is undergoing transformative shifts driven by multiple converging forces that reshape both capability and adoption. First, instrument innovation continues to prioritize speed, accuracy, and cost-efficiency, enabling new use cases such as rapid infectious disease pathogen identification and real-time oncology monitoring. Second, bioinformatics has shifted from bespoke scripts to increasingly standardized, validated pipelines that incorporate alignment, annotation, and variant calling with reproducible outputs suitable for clinical reporting. These methodological advances reduce variability between laboratories and accelerate time-to-result, which in turn amplifies the clinical and commercial value proposition of NGS.

Concurrently, data management and storage paradigms have evolved; stakeholders increasingly adopt hybrid architectures that combine cloud storage with on-premise compute to reconcile data sovereignty, latency, and security concerns. Integration with electronic health records and clinical decision support tools is becoming more seamless, enabling genomic insights to inform point-of-care decisions. Regulatory frameworks are adapting to this reality, with a stronger focus on analytical and clinical validation, software-as-a-medical-device considerations, and the provenance of reference data sets. Finally, collaboration models are shifting as partnerships between academic centers, diagnostic labs, and biopharma accelerate co-development of assays and companion diagnostics. Together, these shifts create a dynamic environment where technical innovation, validation rigor, and ecosystem partnerships jointly determine the rate and scope of NGS adoption.

How 2025 tariff measures reshaped sequencing supply chains, procurement behaviors, and operational resilience strategies across laboratories and service providers

The introduction of tariffs by the United States in 2025 has exerted a multifaceted influence on next generation sequencing supply chains, procurement strategies, and cost-management practices without altering the underlying scientific value of genomic technologies. Tariff measures affected the flow of instruments, reagents, and ancillary components by increasing landed costs for imported items and prompting organizations to re-evaluate supplier diversification. As a result, procurement teams accelerated vendor qualification processes for regional suppliers and sought longer-term contracts to stabilize pricing and supply commitments. In parallel, manufacturers and distributors adjusted inventory strategies, maintaining higher buffer stocks and revisiting manufacturing footprints to mitigate the risk of tariff-related disruptions.

Operationally, laboratories and service providers adapted by optimizing reagent utilization, consolidating orders, and negotiating bundled service agreements that absorb some tariff-driven cost pressures. For institutions prioritizing clinical continuity, the emphasis shifted toward validated local sourcing and strengthened service-level agreements to ensure instrument uptime. Furthermore, the tariff environment prompted a reassessment of capital allocation timelines: organizations weighed the benefits of acquiring new high-throughput sequencers against incremental import costs and potential delays. At the same time, regulatory compliance and quality control requirements remained non-negotiable, driving investments in workflow efficiencies that preserve analytical performance even as procurement dynamics change. In essence, the cumulative effect of tariffs in 2025 accelerated supply-chain resilience planning and reinforced the importance of integrated procurement and operational strategies to sustain sequencing programs.

Integrated segmentation analysis that aligns technology types, product categories, workflow stages, end-user profiles, and application-driven priorities to guide strategic investment

Key segmentation insights reveal where technological strengths and workflow demands intersect to shape adoption and capability priorities. Based on Technology, the landscape spans Amplicon Sequencing, Gene Panel Sequencing, RNA Sequencing, Targeted Sequencing, Whole Exome Sequencing (WES), and Whole Genome Sequencing (WGS), each offering a distinct balance of depth, breadth, and clinical utility that informs platform and assay selection. Based on Product Type, offerings are organized across Consumables Reagents, Instruments, and Software Services; within Consumables Reagents the focus narrows to Enzymes and Kits, while Instruments distinguish Ancillary Instruments from Sequencers, and Software Services break down into Data Analysis Software and Services, reflecting the rising importance of validated analytics and managed interpretation.

Based on Workflow, critical stages include Data Analysis, Data Storage, Sample Preparation, and Sequencing; Data Analysis further segments into Alignment, Annotation, and Variant Calling, Data Storage differentiates Cloud Storage from On-Premise Storage, and Sample Preparation separates Library Preparation from Template Preparation, underscoring that bottlenecks can occur at multiple touchpoints beyond the sequencer itself. Based on End User, adoption patterns differ among Academic Research Institutes, Healthcare Diagnostic Laboratories, and Pharmaceutical Biotechnology Companies, each of which prioritizes different performance metrics, regulatory rigor, and scale considerations. Based on Application, deployments range across Agrigenomics, Carrier screening, Epigenomics, Forensic Genomics, Genetic & Rare Diseases, Infectious Diseases, Neurogenomics, Oncology, and Pharmacogenomics, demonstrating that application-specific requirements drive assay design, data interpretation needs, and downstream clinical or commercial pathways.

Taken together, these segmentation lenses show that strategic investments should align technology choice with specific workflow pinch points and end-user requirements, while emphasizing interoperable analysis and storage solutions that accommodate diverse applications and validation needs.

Regional deployment dynamics that influence sequencing adoption, regulatory alignment, and infrastructure investments across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics continue to shape how next generation sequencing capabilities roll out and scale across different health systems, research networks, and commercial ecosystems. In the Americas, deployment trends emphasize clinical diagnostics, oncology applications, and a robust diagnostics services market supported by advanced bioinformatics providers and cloud-native storage solutions. North American academic centers and biotech hubs drive method validation and translational research, while commercial lab networks focus on assay standardization and high-throughput workflows.

In Europe, Middle East & Africa, regulatory harmonization, data protection frameworks, and diverse healthcare reimbursement models influence adoption cadence. European research consortia and national public health initiatives frequently collaborate to establish reference standards, while regional manufacturers and service providers respond to varying data sovereignty requirements by offering localized storage and compute options. Emerging hubs in the Middle East and North Africa are investing in sequencing capacity for public health surveillance and precision medicine pilot programs.

Across Asia-Pacific, growth patterns reflect a mix of government-led sequencing initiatives, expansive clinical sequencing adoption in select markets, and strong manufacturing capabilities for instruments and reagents. Several countries prioritize genomics for population health, infectious disease surveillance, and agriculture, prompting significant investments in laboratory infrastructure and workforce training. In each region, the balance of public and private funding, regulatory pathways, and local academic-industry collaborations determines how sequencing technologies are integrated into broader healthcare and research agendas.

Competitive ecosystem analysis revealing how instrument makers, reagent suppliers, analytics vendors, and service laboratories converge to offer integrated sequencing value propositions

Competitive positioning in the sequencing ecosystem reflects a blend of instrument manufacturers, reagent suppliers, software and analytics providers, and service laboratories, each pursuing distinct value propositions. Leading instrument providers concentrate on throughput, accuracy, and integrated workflow solutions, while reagent and kit suppliers emphasize reliability, lot-to-lot consistency, and regulatory-ready documentation to meet clinical validation needs. Software and services vendors differentiate through validated analysis pipelines, interpretive content, and managed services that reduce the interpretive burden on laboratories and clinicians.

Service laboratories and contract research organizations play a complementary role by offering scalable sequencing capacity, assay development partnerships, and decentralized testing models that allow clinical and research customers to access advanced capabilities without immediate capital investment. Strategic partnerships and licensing deals increasingly blur traditional vendor boundaries, as companies combine hardware, consumables, and analytic services into cohesive offerings that accelerate end-to-end validation. In response, purchasers evaluate vendors not only on instrument specifications but also on ecosystem support, data portability, and long-term roadmap commitments that ensure compatibility with evolving clinical standards and bioinformatic requirements.

Practical strategic guidance for leaders to align technology selection, data infrastructure, supply resilience, and partnership models to scale sequencing responsibly

Actionable recommendations for industry leaders focus on aligning technology selection, operational design, and partnership strategies to capture the full potential of sequencing while managing risks related to validation, supply chain, and data governance. First, prioritize modular and validated workflows that allow incremental scaling; selecting platforms and consumables that interoperate with standardized analysis pipelines reduces time-to-clinical-readiness and simplifies regulatory pathways. Second, invest in hybrid data architectures that balance cloud scalability with on-premise control to meet data sovereignty requirements and latency-sensitive clinical use cases. Third, develop supplier diversity strategies and longer-term procurement agreements that address tariff and supply disruption risks while preserving quality and documentation standards required for clinical use.

Additionally, cultivate strategic partnerships that extend beyond transactional procurement: co-development agreements with assay developers, data-sharing partnerships with academic centers, and managed service arrangements with analytics providers accelerate validation and broaden access. Upskilling laboratory staff in bioinformatics and quality systems is essential to maintain analytical rigor as workflows scale, and embedding interpretive expertise into clinical reports will improve clinician confidence and patient outcomes. Finally, regularly assess regulatory trajectories and engage with standards-setting bodies to ensure that internal validation programs and software development practices remain aligned with emerging guidance. These steps together create a resilient, scalable pathway from laboratory innovation to routine clinical impact.

A triangulated research methodology combining primary stakeholder interviews, laboratory workflow benchmarking, and secondary validation to produce robust sequencing insights

The research methodology underpinning this report synthesizes primary stakeholder interviews, laboratory workflow analyses, and rigorous secondary-source validation to ensure evidence-based conclusions. Primary inputs included consultations with instrument engineers, clinical laboratory directors, bioinformatics leaders, and procurement specialists to capture real-world constraints and innovation priorities. These qualitative engagements were complemented by structured workflow observations and technical benchmark assessments that focused on sequencing accuracy, time-to-result, and integration challenges across sample preparation, sequencing, and analysis stages.

Secondary validation incorporated peer-reviewed literature, regulatory guidance documents, and technology white papers to corroborate trends identified in primary research and to contextualize developments in bioinformatics and data management. Where applicable, comparative assessments of analytical pipelines-covering alignment, annotation, and variant calling-were performed to highlight reproducibility considerations and interpretive bottlenecks. The methodology emphasizes triangulation across data sources, transparency in assumptions, and clarity about the limits of inference, ensuring that findings are both actionable and grounded in a robust evidence base. Throughout, the approach maintained strict attention to data integrity, reproducibility, and the practical needs of laboratory and clinical stakeholders.

Concluding synthesis emphasizing that validated workflows, resilient operations, and collaborative execution unlock the full clinical and research value of sequencing technologies

This executive summary synthesizes the strategic realities of next generation sequencing: technological advances have expanded application breadth and clinical relevance, while operational complexities related to workflows, data, and procurement determine effective adoption. Stakeholders must approach sequencing as a systems challenge that spans instrument selection, validated consumables, interoperable analytics, and resilient supply chains. Emerging regulatory emphasis on validation and software integrity increases the premium on reproducible pipelines and documented quality management systems, and tariff-related procurement dynamics highlight the necessity of diversified sourcing and strategic vendor relationships.

Looking forward, the most successful organizations will combine technical excellence with operational foresight-investing in hybrid data infrastructures, workforce upskilling, and collaborative partnerships that accelerate validation and clinical integration. By focusing on validated workflows, robust data governance, and adaptive procurement strategies, leaders can translate sequencing capabilities into measurable research and clinical value. This conclusion underscores that the promise of genomic technologies will be realized not solely through isolated innovations, but through disciplined execution across the full sequencing ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of single-cell multiomics and spatial transcriptomics for precision oncology
  • 5.2. Expansion of long-read sequencing applications in structural variant analysis and diagnostics
  • 5.3. Adoption of real-time nanopore sequencing for on-site infectious disease surveillance and control
  • 5.4. Implementation of automated NGS library preparation systems to reduce turnaround times and errors
  • 5.5. Growth of AI and machine learning platforms for accelerated NGS data analysis and interpretation
  • 5.6. Emergence of direct RNA sequencing methods to improve transcriptome profiling accuracy and throughput
  • 5.7. Rising adoption of liquid biopsy NGS assays for early cancer detection and minimal residual disease monitoring
  • 5.8. Integration of cloud-native bioinformatics pipelines for scalable and secure NGS data management workflows
  • 5.9. Expansion of regulatory approvals and reimbursement pathways for NGS-based companion diagnostics in oncology
  • 5.10. Development of synthetic long-read technologies to resolve complex genomic regions and haplotype phasing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next Generation Sequencing Market, by Technology

  • 8.1. Amplicon Sequencing
  • 8.2. Gene Panel Sequencing
  • 8.3. RNA Sequencing
  • 8.4. Targeted Sequencing
  • 8.5. Whole Exome Sequencing (WES)
  • 8.6. Whole Genome Sequencing (WGS)

9. Next Generation Sequencing Market, by Product Type

  • 9.1. Consumables Reagents
    • 9.1.1. Enzymes
    • 9.1.2. Kits
  • 9.2. Instruments
    • 9.2.1. Ancillary Instruments
    • 9.2.2. Sequencers
  • 9.3. Software Services
    • 9.3.1. Data Analysis Software
    • 9.3.2. Services

10. Next Generation Sequencing Market, by Workflow

  • 10.1. Data Analysis
    • 10.1.1. Alignment
    • 10.1.2. Annotation
    • 10.1.3. Variant Calling
  • 10.2. Data Storage
    • 10.2.1. Cloud Storage
    • 10.2.2. On-Premise Storage
  • 10.3. Sample Preparation
    • 10.3.1. Library Preparation
    • 10.3.2. Template Preparation
  • 10.4. Sequencing

11. Next Generation Sequencing Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Healthcare Diagnostic Laboratories
  • 11.3. Pharmaceutical Biotechnology Companies

12. Next Generation Sequencing Market, by Application

  • 12.1. Agrigenomics
  • 12.2. Carrier screening
  • 12.3. Epigenomics
  • 12.4. Forensic Genomics
  • 12.5. Genetic & Rare Diseases
  • 12.6. Infectious Diseases
  • 12.7. Neurogenomics
  • 12.8. Oncology
  • 12.9. Pharmacogenomics

13. Next Generation Sequencing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Next Generation Sequencing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Next Generation Sequencing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Illumina, Inc.
    • 16.3.2. Thermo Fisher Scientific Inc.
    • 16.3.3. Roche Holding AG
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. bioMerieux S.A.
    • 16.3.6. Merck KGaA
    • 16.3.7. Oxford Nanopore Technologies Ltd.
    • 16.3.8. Agilent Technologies, Inc.
    • 16.3.9. Danaher Corporation
    • 16.3.10. F. Hoffmann-La Roche Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEXT GENERATION SEQUENCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEXT GENERATION SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT GENERATION SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS